Primer probe combination, kit, detection system and detection method for novel coronavirus variant typing detection
Through the combination of ARMS-qPCR technology and specific primer probes, the problems of low throughput, time and high cost in the detection of subtypes of novel coronavirus variant strains were solved, and 10 mutation sites with fast, accurate and low cost were achieved. Screening and identification are suitable for the detection of various Omicron variant subtypes.
Patent Information
- Application Number
- CN202410816814.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-24
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art has problems of low detection throughput, long time, complicated operation, low resolution and high cost when detecting subtypes of the novel coronavirus variant. In particular, it is difficult to detect subtypes of the Omicron variants quickly and accurately. It is carried out at low cost.
Using ARMS-qPCR technology to develop a primer probe combination, kit and detection system for detecting the typing of the new coronavirus mutant strain. By designing specific primers and probe combinations, 10 mutations of the new coronavirus mutant strain can be detected simultaneously. loci, achieving rapid and accurate identification of subtypes.
It has achieved rapid, simple, high sensitivity, strong specificity and low cost screening and identification of 10 mutation sites of the novel coronavirus variant strain, avoiding the defects of sequencing and ordinary Taqman probe method, and accurately identifying BA. 5.2. BF.7.14, XBB.1.19.1 and other subtypes are suitable for the classification detection of the currently prevalent subtypes of the novel coronavirus variant strain.
Smart Images

Figure CN118995998A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of nucleic acid detection technology and relates to the detection of novel coronavirus variant subtypes, and specifically relates to a primer probe combination, a kit, a detection system and a detection method for typing detection of novel coronavirus variants. Background Art
[0002] The new coronavirus (SARS-CoV-2) is a single-stranded positive-strand RNA virus. Most clinical symptoms include fever, dry cough, muscle pain, etc. Some severe cases may develop acute respiratory distress syndrome and death. Currently, SARS-CoV-2 has evolved into a variety of mutant strains, such as Alpha, Beta, Gamma, Delta, and Omicron variants. These variants have been listed as variants of concern (VOC) by the World Health Organization (WHO), indicating that they may have high transmission ability or strong pathogenicity, and may reduce the effectiveness of current drugs and COVID-19 vaccines, thus attracting global attention.
[0003] At present, the novel coronavirus variants prevalent in various countries around the world are basically different subtypes of the Omicron variant. According to GISAID data, there are currently hundreds of subtypes of the Omicron variant. The real-time frequency monitoring data of mutants show that the top few are mainly the XBB variant subtype series, followed by the BA.5.2 and BF.7.14 subtype series. Detection of these mutants helps to monitor the changes in the epidemic trend of novel coronavirus mutants in real time, and helps to indicate whether there is a risk of new mutants. At present, the main methods for determining mutation sites are sequencing, fluorescent PCR, etc. Among them, sequencing methods include first-generation sequencing, second-generation sequencing, and third-generation sequencing represented by nanopore sequencing. First-generation sequencing is known as the gold standard of all generations of sequencing methods, but its detection throughput is low and time-consuming. The second-generation sequencing has a high detection throughput, but the operation is cumbersome and time-consuming, and professional personnel are required to perform bioinformatics analysis on the results after the test. The read length of the third-generation sequencing is longer, but the error rate is much higher than that of the first and second-generation sequencing, and it is not suitable for the detection of point mutations. Fluorescence PCR can be combined with Taqman probes or MGB probes to identify point mutations. However, Taqman probes have a low resolution for point mutations and cannot effectively distinguish point mutations. MGB probes have a higher resolution than Taqman probes, but the price of MGB probes is higher and the synthesis cycle is longer.
[0004] ARMS-PCR (amplification refractory mutation system, ARMS-PCR) is a method used to detect known mutations. Its basic principle is that if the 3' end base of the primer is not complementary to the template base, it cannot be extended by a general thermostable DNA polymerase (without 3'-5' exonuclease activity) (in fact, there is still some amplification, which is manifested as a sharp reduction in the product due to the 3' base mismatch of the primer under certain conditions, and the intuitive manifestation is the significant backward shift of the CT value). Therefore, the present invention adopts ARMS-qPCR technology to develop a primer-probe combination, a kit, a detection system and a detection method for detecting the typing of novel coronavirus variants. According to each known point mutation, two primers are designed (the first base at the 3′ end of one primer is the mutant base to be detected, and this primer can be an upstream primer or a downstream primer, and the other primer is a normal base sequence primer) and a Taqman probe. When the primer containing the 3′ mutant base is complementary to the mutant template and the wild template base, respectively, because the primer containing the 3′ end mutant base can completely match the mutant template, the amplification process proceeds normally, and the CT value is normal after the amplification is completed; but it cannot completely match the wild template, resulting in amplification being blocked, the amplification product is significantly reduced, and the CT value is delayed after the amplification is completed. By making a difference with the CT value of the reference gene, the template with a certain point mutation is distinguished from the normal template, and the identification of the point mutation is realized. Compared with the sequencing method, the ordinary Taqman probe method and the MGB probe method, the ARMS-qPCR method has the advantages of simple operation, strong specificity, high sensitivity, low price, and short detection cycle.
[0005] For example, patents CN114085928B and CN113943838A both provide kits for detecting and typing the novel coronavirus Omicron mutant strains using ARMS-PCR. Both kits have high specificity, sensitivity and accuracy, but they are mainly used to detect the Omicron BA series strains. Although patent CN117344060A provides typing detection methods for BA.5.2, BF.7, XBB.1, BQ.1.1 and EQ.5 based on Taqman probes, these basic strains now have variants. For example, XBB.1.5 has similar immune escape ability to XBB.1, but XBB.1.5 also has an additional mutation F486P, which makes it bind more tightly to the ACE2 receptor and increases the ease of infection. Therefore, it is necessary to develop a rapid, accurate, highly sensitive, low-cost typing detection method applicable to the currently prevalent novel coronavirus mutant strain subtypes. Summary of the invention
[0006] Terms and Claims of the Present Invention: The method for detecting the typing of novel coronavirus variants of the present invention is not used for diagnosis, or in other words, the qualitative and quantitative results of detecting novel coronavirus variant subtypes have no one-to-one correlation with whether the disease occurs, and do not belong to diagnostic results. However, the detection results of novel coronavirus variant subtypes can be used as intermediate information for reference by clinicians.
[0007] In response to the problems existing in the prior art, the present invention provides a primer probe combination, a kit, a detection system and a detection method for typing detection of novel coronavirus variants, and can accurately identify 10 coronavirus Omicron variant subtypes, namely BA.5.2, BF.7.14, XBB.1.19.1, XBB.1.16, XBB.1.9, XBB.1.5, XBB.1.22.1, EG.5, EG.5.1 and XBB.2.3.
[0008] To achieve the above purpose, the technical solution adopted by the present invention is as follows: In the first aspect, the present invention provides a primer-probe combination for detecting the typing of novel coronavirus variants, the primer-probe combination comprising: primers with sequences as shown in SEQ ID NO.3-22 and probes with sequences as shown in SEQ ID NO.26-35.
[0009] Specifically, the primer-probe combination also includes a primer probe for detecting a reference gene and a primer probe for detecting a positive internal quality control product.
[0010] Further specifically, the primer probe set for detecting the reference gene includes primers with sequences as shown in SEQ ID NO.1-2 and a probe with a sequence as shown in SEQ ID NO.25; the primer probe for detecting the positive internal control product includes primers with sequences as shown in SEQ ID NO.23-24 and a probe with a sequence as shown in SEQ ID NO.36.
[0011] Specifically, the two ends of the probe carry a fluorescent group and a quenching group respectively.
[0012] Further specifically, the probes shown in SEQ ID NO.25, 29, and 33 have a first fluorescent marker; the probes shown in SEQ ID NO.26, 30, and 34 have a second fluorescent marker; the probes shown in SEQ ID NO.27, 31, and 35 have a third fluorescent marker; the probes shown in SEQ ID NO.28, 32, and 36 have a fourth fluorescent marker; the first fluorescent marker, the second fluorescent marker, the third fluorescent marker, and the fourth fluorescent marker are different, and are each independently selected from one of a FAM fluorescent marker, a VIC fluorescent marker, a CY5 fluorescent marker, and a ROX fluorescent marker, and the quenching group is selected from any one or more of BHQ1, BHQ2, and BHQ3.
[0013] On the other hand, the present invention also provides the use of the above-mentioned primer-probe combination in the preparation of a kit for detecting typing of novel coronavirus variants.
[0014] In yet another aspect, the present invention also provides a kit comprising the primer-probe combination as described above.
[0015] Specifically, the kit divides the above twelve sets of primer-probe combinations into tube A, tube B and tube C; tube A contains primers shown in SEQ ID NO.1-8 and probes shown in SEQ ID NO.25-28; tube B contains primers shown in SEQ ID NO.9-16 and probes shown in SEQ ID NO.29-32; tube C contains primers shown in SEQ ID NO.17-24 and probes shown in SEQ ID NO.33-36.
[0016] More specifically, the kit further comprises at least one of a reaction system buffer, a reverse transcriptase, a UDG enzyme, an RNase inhibitor, a DNA polymerase, Tween-20, potassium ions, magnesium ions, dNTPs, a positive control and water.
[0017] More specifically, the sample to be tested can be a throat swab, a nasopharyngeal swab, sputum, a sewage sample, etc., and a commercial kit can be used to process the sample to be tested to obtain the RNA to be tested as an amplification template.
[0018] More specifically, the kit also includes a positive control and a reference gene, wherein the positive control is the RNaseP gene; and the reference gene is the S gene.
[0019] On the other hand, the present invention provides the use of the above-mentioned components in the preparation of a kit for detecting subtypes of novel coronavirus variants.
[0020] In another aspect, the present invention also provides a system for simultaneously detecting 10 subtypes of novel coronavirus variants. Specifically, the system includes an A tube detector, a B tube detector, a C tube detector, a PCR instrument, a memory and a processor.
[0021] More specifically, the A tube detector, the B tube detector and the C tube detector are respectively loaded with the primer-probe combination described in claims 1-5.
[0022] Further specifically, the PCR instrument includes a first fluorescent channel, a second fluorescent channel, a third fluorescent channel and a fourth fluorescent channel, the first fluorescent channel, the second fluorescent channel, the third fluorescent channel and the fourth fluorescent channel are different, and each is independently selected from one of the FAM fluorescent channel, the VIC fluorescent channel, the CY5 fluorescent channel or the ROX fluorescent channel, and the quenching group is selected from any one or more of BHQ1, BHQ2, and BHQ3.
[0023] Further specifically, the memory stores a computer program, and the processor is configured to execute the computer program stored in the memory to achieve the following determination: If the blank control, positive control and positive internal control are established, the test results are valid; Positive and negative determination: If the CT value of the positive internal quality control test is ≤38, the test result is reliable; if the CT value of the new coronavirus reference gene is ≤40, it is judged to be SARS-CoV-2 positive; if the Ct value of the ORF1ab, S, ORF7a, and ORF8 gene mutation site detection is ≤40.0 and the ΔCt with the reference gene is ≤4.0, the site is positive; Identification of subtypes of Omicron variants: Subtype determination was performed on the sites that tested positive, namely the mutation sites. The mutants BA.5.2 all contained P543S mutations, and some BA.5.2 mutants contained T4175I mutations; the mutants BF.7.14 all contained C1243F mutations, and some BF.7.14 mutants contained P543S mutations; the mutants XBB.1.19.1 all contained E554K mutations; the mutants XBB.1.16 all contained E180V mutations, and some XBB.1.16 mutants contained G8 mutations; the mutants XBB.1.9 all contained T4175I Mutations, some XBB.1.9 variants contain G8 mutations; all XBB.1.5 variants contain G8 mutations; all XBB.1.22.1 variants contain Y200C mutations, and some XBB.1.22.1 variants contain G8 mutations; all EG.5 variants contain F456L mutations, and some EG.5 variants contain G8 mutations; all EG.5.1 variants contain Q52H mutations, and some EG.5.1 variants contain G8 mutations; all XBB.2.3 variants contain A13V mutations, and some XBB.2.3 variants contain G8 mutations.
[0024] In another aspect, the present invention also provides a method for simultaneously detecting 10 mutation sites of a novel coronavirus variant and identifying 10 subtypes of the novel coronavirus variant, the detection method comprising the following steps: (1) using the above primer-probe combination to amplify the sample to be tested using the above PCR instrument; (2) using the above-mentioned computing device to make a determination; Specifically, the PCR amplification system can be: total system 25 μL, 2×PCR buffer 12.5 μL, 12.5×enzyme mixture 2 μL, 10×primer probe mixture 2.5 μL, template 5 μL, ultrapure water 3 μL.
[0025] Specifically, the conditions for PCR amplification can be: a: 50℃, 10min; b: 95℃, 30s; c: 95℃, 5s, d: 60°C, 30 s; cd cycle of 45 reactions, and fluorescence was collected at the corresponding stages.
[0026] Compared with the prior art, the present invention has the following beneficial effects: The present invention can quickly screen and identify 10 mutation sites of novel coronavirus variants in the sample to be tested, and identify 10 subtypes of novel coronavirus variants according to the mutation sites, avoiding the problems of long detection cycle, low resolution, high price, low sensitivity and complicated operation existing in sequencing methods, ordinary Taqman probe method and MGB probe method, and achieves the following detection effects: 1. High multiplex detection capability The detection method established by the present invention can quickly and easily identify the virus type by simultaneously detecting 10 mutation sites of the new coronavirus variant in three reaction systems, saving time, manpower and reagent costs.
[0027] 2. High sensitivity The detection method established by the present invention can realize the simultaneous detection of 10 mutation sites of the novel coronavirus variant. The ARMS-qPCR method has high sensitivity, and the detection sensitivity of each target gene in the reaction system can reach 2×10 2 copies∕mL, which is comparable to the sensitivity of single-plex real-time fluorescence PCR detection.
[0028] 3. High specificity In the detection method established by the present invention, the last base at the 3' end of the primer is consistent with the mutation site sequence, which ensures the high specificity of the ARMS-qPCR method amplification. All primers are subjected to BLAST comparison analysis and are highly conservative and specific. They can not only distinguish the detection targets from each other, but also distinguish them from other pathogens with the same living environment, including SARS coronavirus, MERS coronavirus, parainfluenza virus, rhinovirus, respiratory syncytial virus, adenovirus, measles virus, mumps virus, human coronavirus NL63 / 229E / OC43 / HKU1 type, human cytomegalovirus, Bordetella pertussis, human metapneumovirus, enterovirus, Chlamydia pneumoniae, Haemophilus influenzae, Neisseria meningitidis, Mycoplasma pneumoniae, Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus pyogenes, Streptococcus salivarius, Legionella, Mycobacterium tuberculosis, etc.
[0029] 4. Low cost In the ARMS-qPCR detection method established in the present invention, only 3 tubes are needed to detect 10 mutant subtypes, which effectively reduces the cost.
[0030] 5. Fast, time-saving and high accuracy In the detection method established by the present invention, the ARMS-qPCR method is less time-consuming than the sequencing method, and the consistency of the detection result and the sequencing result is as high as 100%.
[0031] (VI) Easy to operate The detection method established in the present invention can be completed using a qPCR instrument commonly used in laboratories, etc., without the need for complicated operating steps.
[0032] 7. Preventing false negative results In the detection method established by the present invention, the use of positive internal quality control can effectively indicate false negative detection results.
[0033] 8. Wide range of application scenarios The detection reagents, kits, detection systems and methods established by the present invention can be widely used in various scenarios such as epidemic population tracing and sewage monitoring. The transmission chain of the epidemic can be analyzed through the detection results, risk places can be tracked and determined, the epidemic trend can be analyzed, and the spread and transmission of the epidemic can be prevented.
[0034] 9. Monitoring and identification of future variants The detection system and detection method established by the present invention provide ideas for the detection of new coronavirus mutant strain subtypes that may appear in the future, facilitating early screening and epidemic monitoring.
[0035] Other features and advantages of the present invention will be described in detail in the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 This is the amplification map of the minimum detection limit experiment of tube A.
[0037] Figure 2 This is the amplification spectrum of the minimum detection limit experiment of tube B.
[0038] Figure 3 This is the amplification map of the minimum detection limit experiment of tube C.
[0039] Figure 4 This is the amplification map of the A-tube specific experiment.
[0040] Figure 5 This is the amplification map of the B-tube specific experiment.
[0041] Figure 6 This is the amplification map of the C tube specific experiment.
[0042] Figure 7 This is the amplification map of the C tube specific experiment. DETAILED DESCRIPTION
[0043] The present invention will be further described in detail below in conjunction with specific examples. The following examples are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are generally conventional, unless otherwise specified, and the materials, reagents, etc. used in the following examples are commercially available, unless otherwise specified.
[0044] Example 1 Detection method (1) Primer and probe synthesis: Sequence synthesis was performed according to the primer sequences shown in Table 1 and the probe sequences shown in Table 2. The probes shown in SEQ ID NOs. 25, 29, and 33 have a first fluorescent marker FAM; the probes shown in SEQ ID NOs. 26, 30, and 34 have a second fluorescent marker VIC; the probes shown in SEQ ID NOs. 27, 31, and 35 have a third fluorescent marker CY5; and the probes shown in SEQ ID NOs. 28, 32, and 36 have a fourth fluorescent marker ROX. Table 1
[0045] Table 2
[0046] (2) Sample processing: After collecting throat swabs, nasopharyngeal swabs, sputum, sewage or other forms of samples from patients by conventional methods, they are extracted using a commercial extraction kit. Once the RNA to be tested is obtained, it can be used as an amplification template.
[0047] (3) Construction of detection system: total system 25 μL, 2× PCR buffer 12.5 μL, 12.5× enzyme mixture 2 μL (Hifair® V C44P12 Multiplex One Step RT-qPCR Probe Kit, Catalog No. 13835ES85), 10× primer-probe mixture (including the positive internal control, the concentration of each primer is 400 nM, the concentration of each probe is 200 nM) 2.5 μL, template 5 μL, ultrapure water 3 μL.
[0048] (4) Placing the detection system into the detection device: Distribute the configured system into three reaction tubes, namely, tube A, tube B and tube C. Tube A contains primers shown in SEQ ID NOs. 1-8 and probes shown in SEQ ID NOs. 25-28; tube B contains primers shown in SEQ ID NOs. 9-16 and probes shown in SEQ ID NOs. 29-32; and tube C contains primers shown in SEQ ID NOs. 17-24 and probes shown in SEQ ID NOs. 33-36.
[0049] (5) PCR amplification: Place the PCR tube into a fluorescent quantitative PCR instrument, select FAM, VIC, CY5, and ROX as reporter groups, and the reaction procedure is as follows: a: 50℃, 10min; b: 95℃, 30s; c: 95℃, 5s, d: 60°C, 30 s; cd cycle of 45 reactions, and fluorescence was collected at the corresponding stages.
[0050] (6) Test result determination: If the blank control, positive control and positive internal quality control are established, the test result is valid; Positive and negative judgment: positive internal quality control test CT value ≤ 38, the test result is reliable. The CT value of the new coronavirus reference gene is ≤ 40, which is judged as SARS-CoV-2 positive; ORF1ab, S, ORF7a, ORF8 gene mutation site detection Ct value ≤ 40.0 and ΔCt ≤ 4.0 with the reference gene, the site is positive.
[0051] Identification of subtypes of Omicron variants: Subtype determination was performed on the sites that tested positive, namely the mutation sites. The mutants BA.5.2 all contained P543S mutations, and some BA.5.2 mutants contained T4175I mutations; the mutants BF.7.14 all contained C1243F mutations, and some BF.7.14 mutants contained P543S mutations; the mutants XBB.1.19.1 all contained E554K mutations; the mutants XBB.1.16 all contained E180V mutations, and some XBB.1.16 mutants contained G8 mutations; the mutants XBB.1.9 all contained T4175I Mutations, some XBB.1.9 variants contain G8 mutations; all XBB.1.5 variants contain G8 mutations; all XBB.1.22.1 variants contain Y200C mutations, and some XBB.1.22.1 variants contain G8 mutations; all EG.5 variants contain F456L mutations, and some EG.5 variants contain G8 mutations; all EG.5.1 variants contain Q52H mutations, and some EG.5.1 variants contain G8 mutations; all XBB.2.3 variants contain A13V mutations, and some XBB.2.3 variants contain G8 mutations.
[0052] The specific determination method of the test results refers to Tables 3 and 4. Under the premise of meeting the quality control standards, the reference gene and detection site are first determined according to the determination rules in Table 3, and then the mutant strain subtype is determined according to Table 4 based on the determination results in Table 3.
[0053] Table 3
[0054] Table 4
[0055] Example 2 Minimum detection limit analysis: (1) Synthesize gene fragments of 10 mutation sites of the novel coronavirus variant, quantify the concentration to 1010 copies / mL, and perform gradient dilution to obtain a concentration of 2×10 5 copies / mL, 2×10 4 copies / mL, 2×10 3 copies / mL, 2×10 2 copies / mL, 2×10 1 copies / mL, 2×100copies / mL test samples.
[0056] (2) According to the detection method of Example 1, the test samples of different concentrations were tested respectively.
[0057] Figure 1 , 23. The results show that the minimum detection limit concentration of the kit of the present invention for detecting 10 mutation sites is 2×10 2 copies / mL, the detection sensitivity of the kit of the present invention is high.
[0058] Example 3 Specificity analysis: (1) Select SARS coronavirus, MERS coronavirus, parainfluenza virus, rhinovirus, respiratory syncytial virus, adenovirus, measles virus, mumps virus, human coronavirus NL63 / 229E / OC43 / HKU1, human cytomegalovirus, Bordetella pertussis, human metapneumovirus, enterovirus, Chlamydia pneumoniae, Haemophilus influenzae, Neisseria meningitidis, Mycoplasma pneumoniae, Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus pyogenes, Streptococcus salivarius, Legionella, Mycobacterium tuberculosis and other bacteria that are close to the target species and have a similar living environment as the specificity evaluation samples.
[0059] (2) Using the kit provided by the present invention, the above-mentioned specific evaluation sample is detected according to the detection method of Example 1. Figure 4 , 5 The results of , 6, and 7 show that under the conditions where the negative control, positive control, and positive internal quality control were all established, no non-specific fluorescent signals appeared in the targets to be detected, indicating that the kit of the present invention can effectively distinguish non-target pathogens and has good specificity.
[0060] Comparative Example 1 Primer and probe selection (1) Perform sequence synthesis according to the primer sequences shown in Table 5.
[0061] Table 5
[0062] (2) All primer probes in Table 1, Table 2 and Table 5 were combined, and the combined primer probes were used to detect the mutant plasmids and wild-type plasmids at each site, respectively. The results are shown in Table 6.
[0063] Table 6
[0064] Finally, the optimal primer-probe combination for each site was screened out, which had the highest efficiency when amplifying mutant plasmids and no non-specific amplification when amplifying wild-type plasmids. The optimal primer-probe combination for each site is shown in Table 7: Table 7
Claims
1. A primer-probe combination for typing detection of novel coronavirus variants, It is characterized in that include: The primers have sequences as shown in SEQ ID NO.3-22 and the probes have sequences as shown in SEQ ID NO.26-35.
2. The primer-probe combination according to claim 1, It is characterized in that It also includes primer probes for detecting reference genes and primer probes for detecting positive internal quality control products.
3. The primer-probe combination according to claim 2, It is characterized in that The primer probe set for detecting the reference gene includes primers with sequences as shown in SEQ ID NO.1-2 and a probe with a sequence as shown in SEQ ID NO.25; the primer probe for detecting the positive internal control product includes primers with sequences as shown in SEQ ID NO.23-24 and a probe with a sequence as shown in SEQ ID NO.
36.
4. The primer-probe combination according to claim 3, It is characterized in that The probes contain fluorescent markers; the probes shown in SEQ ID NOs.25, 29, and 33 have a first fluorescent marker; the probes shown in SEQ ID NOs.26, 30, and 34 have a second fluorescent marker; the probes shown in SEQ ID NOs.27, 31, and 35 have a third fluorescent marker; the probes shown in SEQ ID NOs.28, 32, and 36 have a fourth fluorescent marker; the first fluorescent marker, the second fluorescent marker, the third fluorescent marker, and the fourth fluorescent marker are different.
5. The fluorescent label according to claim 4, Features: The fluorescent labels are independently selected from one of FAM fluorescent labeling, VIC fluorescent labeling, CY5 fluorescent labeling and ROX fluorescent labeling; the quenching group is selected from any one or more of BHQ1, BHQ2 and BHQ3.
6. Use of the primer-probe combination according to any one of claims 1 to 5 in the preparation of a kit for typing and detecting novel coronavirus variants.
7. The use according to claim 6, Features: The kit for detecting the typing of novel coronavirus variants comprises the following steps: (1) Extract RNA from the sample to be tested; (2) using the primer-probe combination according to any one of claims 1 to 5 to perform multiplex real-time fluorescence PCR amplification; (3) Collecting fluorescence signals and determining whether there is a mutation based on the fluorescence signals; (4) Determine the subtype of the novel coronavirus variant based on the mutation site.
8. The use according to claim 7, It is characterized in that In the primer-probe combination in step (2), the primer concentration is 0.005-1.0 μmol; the probe concentration is 0.005-1.0 μmol.
9. The use according to claim 8, It is characterized in that In the step (2), the multiplex real-time fluorescence PCR amplification system is: total system 25 μL, 2×PCR buffer 12.5 μL, 12.5×enzyme mixture 2 μL, 10×primer probe mixture 2.5 μL, template 5 μL, ultrapure water 3 μL.
10. The use according to claim 7, It is characterized in that In the step (2), the multiplex real-time fluorescence PCR amplification procedure is: a: 50℃, 10min; b: 95℃, 30s; c: 95℃, 5s, d: 60°C, 30 s; cd cycle of 45 reactions, and fluorescence was collected at the corresponding stages.
11. The use according to claim 7, It is characterized in that The judgment criteria of step (3) are: (1) Positive and negative determination: If the CT value of the positive internal quality control test is ≤38, the test result is reliable; (2) If the CT value of the novel coronavirus reference gene is ≤40, it is considered positive for SARS-CoV-2; (3) If the Ct value of the mutation site in ORF1ab, S, ORF7a, or ORF8 is ≤40.0 and the ΔCt value compared with the reference gene is ≤4.0, the mutation site is positive; Judgment criteria for step (4): All BA.5.2 variants contain P543S mutations, and some BA.5.2 variants contain T4175I mutations; all BF.7.14 variants contain C1243F mutations, and some BF.7.14 variants contain P543S mutations; all XBB.1.19.1 variants contain E554K mutations; all XBB.1.16 variants contain E180V mutations, and some XBB.1.16 variants contain G8 mutations; all XBB.1.9 variants contain T4175I mutations, and some X The BB.1.9 variant contains the G8 mutation; the XBB.1.5 variants all contain the G8 mutation; the XBB.1.22.1 variants all contain the Y200C mutation, and some XBB.1.22.1 variants contain the G8 mutation; the EG.5 variants all contain the F456L mutation, and some EG.5 variants contain the G8 mutation; the EG.5.1 variants all contain the Q52H mutation, and some EG.5.1 variants contain the G8 mutation; the XBB.2.3 variant contains the A13V mutation, and some XBB.2.3 variants contain the G8 mutation.
12. A kit, It is characterized in that The invention comprises the primer-probe combination according to any one of claims 1 to 5.
13. The kit according to claim 12, It is characterized in that The kit also includes any one or more of a reaction system buffer, a reverse transcriptase, a UDG enzyme, an RNase inhibitor, a DNA polymerase, Tween-20, potassium ions, magnesium ions, dNTPs, a positive control and water.
14. Use of the kit described in any one of claims 12-13 in typing detection of novel coronavirus variants for non-disease diagnosis or treatment.
15. A method for detecting subtypes of novel coronavirus variants, It is characterized in that The method is not a disease diagnosis or treatment method, and comprises the following steps: (1) Extract RNA from the sample to be tested; (2) using the primer-probe combination according to any one of claims 1 to 5 to perform multiplex real-time fluorescence PCR amplification; (3) Collecting fluorescence signals and determining whether there is a mutation based on the fluorescence signals; (4) Determine the subtype of the novel coronavirus variant based on the mutation site.
16. A system for simultaneously detecting 10 mutation sites of a novel coronavirus variant. Features: The system comprises a PCR instrument having an A tube detector, a B tube detector, a C tube detector, a computing device and an output device.
17. The detection system according to claim 16, It is characterized in that The A tube detector, the B tube detector and the C tube detector are respectively loaded with the primer-probe combination according to any one of claims 1 to 5.
18. The detection system according to claim 16, It is characterized in that The PCR instrument comprises a first fluorescent channel, a second fluorescent channel, a third fluorescent channel and a fourth fluorescent channel; the first fluorescent channel, the second fluorescent channel, the third fluorescent channel and the fourth fluorescent channel are different from each other.
19. The detection system according to claim 18, It is characterized in that The fluorescent channels are each independently selected from one of a FAM fluorescent channel, a VIC fluorescent channel, a CY5 fluorescent channel and a ROX fluorescent channel.
20. The detection system according to claim 16, It is characterized in that The computing device includes a memory and a processor.
21. The computing device of claim 16, It is characterized in that The memory stores a computer program, and the processor is configured to execute the computer program stored in the memory to achieve the following determination: (1) Positive and negative determination: The judgment criteria are as follows: if the CT value of the positive internal quality control test is ≤38, the test result is reliable; if the CT value of the new coronavirus reference gene is ≤40, it is judged to be SARS-CoV-2 positive; if the Ct value of the ORF1ab, S, ORF7a, and ORF8 gene mutation site test is ≤40.0 and the ΔCt value with the reference gene is ≤4.0, the site is positive; (2) Identification of subtypes of Omicron variants: The judgment criteria are as follows: All BA.5.2 variants contain P543S mutations, and some BA.5.2 variants contain T4175I mutations; all BF.7.14 variants contain C1243F mutations, and some BF.7.14 variants contain P543S mutations; all XBB.1.19.1 variants contain E554K mutations; all XBB.1.16 variants contain E180V mutations, and some XBB.1.16 variants contain G8 mutations; all XBB.1.9 variants contain T4175I mutations. mutation, and some XBB.1.9 variants contain G8 mutations; all XBB.1.5 variants contain G8 mutations; all XBB.1.22.1 variants contain Y200C mutations, and some XBB.1.22.1 variants contain G8 mutations; all EG.5 variants contain F456L mutations, and some EG.5 variants contain G8 mutations; all EG.5.1 variants contain Q52H mutations, and some EG.5.1 variants contain G8 mutations; all XBB.2.3 variants contain A13V mutations, and some XBB.2.3 variants contain G8 mutations.
22. A method for detecting 10 mutation sites of a coronavirus variant and determining its subtype simultaneously using the system of claim 16, It is characterized in that The following steps are involved: (1) Synthesize the primer-probe combination and divide it into three reaction tubes: tube A, tube B, and tube C; (2) Extracting RNA from samples; (3) Configure the reaction system; (4) The reaction system is placed in the system described in claim 16 to perform PCR amplification, and a computer determines the result based on the fluorescent signal.
23. The detection method according to claim 22, It is characterized in that The PCR amplification system in step (4) is: total system 25 μL, 2×PCR buffer 12.5 μL, 12.5×enzyme mixture 2 μL, 10×primer probe mixture 2.5 μL, template 5 μL, ultrapure water 3 μL, multiplex real-time fluorescence PCR amplification program is: a: 50℃, 10min; b: 95℃, 30s; c: 95℃, 5s, d: 60°C, 30 s; cd cycle of 45 reactions, and fluorescence was collected at the corresponding stages.
24. The use according to claim 22, It is characterized in that The judgment criteria of step (4) are: (1) Positive and negative determination: If the CT value of the positive internal quality control test is ≤38, the test result is reliable; (2) If the CT value of the novel coronavirus reference gene is ≤40, it is considered positive for SARS-CoV-2; (3) If the Ct value of the mutation site in ORF1ab, S, ORF7a, or ORF8 is ≤40.0 and the ΔCt value compared with the reference gene is ≤4.0, the mutation site is positive; Judgment criteria for step (4): All BA.5.2 variants contain P543S mutations, and some BA.5.2 variants contain T4175I mutations; all BF.7.14 variants contain C1243F mutations, and some BF.7.14 variants contain P543S mutations; all XBB.1.19.1 variants contain E554K mutations; all XBB.1.16 variants contain E180V mutations, and some XBB.1.16 variants contain G8 mutations; all XBB.1.9 variants contain T4175I mutations, and some X The BB.1.9 variant contains the G8 mutation; the XBB.1.5 variants all contain the G8 mutation; the XBB.1.22.1 variants all contain the Y200C mutation, and some XBB.1.22.1 variants contain the G8 mutation; the EG.5 variants all contain the F456L mutation, and some EG.5 variants contain the G8 mutation; the EG.5.1 variants all contain the Q52H mutation, and some EG.5.1 variants contain the G8 mutation; the XBB.2.3 variant contains the A13V mutation, and some XBB.2.3 variants contain the G8 mutation.
